SPEED UP OF THE DRUG DISCOVERY PROCESS
Strong reduction of the time required to pass from a preclinical validation to a phase I clinical trial, predicting at the same time the outcome of the phase II clinical trials.
OPTIMIZATION OF CLINICAL STUDIES
Drastic reduction of the number of in vivo experiments, which means significant costs saving.
IMPROVEMENT OF THE DESIGN OF EXISTING EXPERIMENTS
Maximization of the chances of success of in vivo / in vitro experiments and reduction of costs and times for clinical validation.
MODELING NEW EXPERIMENTAL STUDIES
Development of new experimental settings, providing a better prediction of the toxicity profile of medical products.